Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of 131I-8H9, a radiolabeled antibody for the treatment of relapsed neuroblastoma

Next Previous
Trial Profile

Study of 131I-8H9, a radiolabeled antibody for the treatment of relapsed neuroblastoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omburtamab-I-131 (Primary)
  • Indications Neuroblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Y-mAbs Therapeutics

    • Most Recent Events

    • 07 Jun 2017 According to a Memorial Sloan-Kettering Cancer Center media release, based on the data from this study, the FDA has granted the Breakthrough Therapy Designation to burtomab for the treatment of pediatric patients with relapsed or refractory neuroblastoma with central nervous system or leptomeningeal metastasis.
    • 04 Jun 2017 Results (n=80) from this trial published in a Y-mAbs Therapeutics Media Release.
    • 28 Sep 2016 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top